about
Thymoquinone subdues tumor growth and potentiates the chemopreventive effect of 5-fluorouracil on the early stages of colorectal carcinogenesis in rats.Sanguisorba officinalis L synergistically enhanced 5-fluorouracil cytotoxicity in colorectal cancer cells by promoting a reactive oxygen species-mediated, mitochondria-caspase-dependent apoptotic pathway.Translationally controlled tumour protein TCTP is induced early in human colorectal tumours and contributes to the resistance of HCT116 colon cancer cells to 5-FU and oxaliplatin.MicroRNAs are important regulators of drug resistance in colorectal cancer.CTGF enhances resistance to 5-FU-mediating cell apoptosis through FAK/MEK/ERK signal pathway in colorectal cancerlncRNA HOTAIR Contributes to 5FU Resistance through Suppressing miR-218 and Activating NF-κB/TS Signaling in Colorectal Cancer.NSC30049 inhibits Chk1 pathway in 5-FU-resistant CRC bulk and stem cell populations.Aldose reductase inhibitor increases doxorubicin-sensitivity of colon cancer cells and decreases cardiotoxicity.Traditional Chinese medicine Danggui Buxue Tang inhibits colorectal cancer growth through induction of autophagic cell death.Effect of AICAR and 5-Fluorouracil on X-ray Repair, Cross-Complementing Group 1 Expression, and Consequent Cytotoxicity Regulation in Human HCT-116 Colorectal Cancer Cells.Cytotoxic effects of the newly-developed chemotherapeutic agents 17-AAG in combination with oxaliplatin and capecitabine in colorectal cancer cell lines.Pacritinib to inhibit JAK/STAT signaling in refractory metastatic colon and rectal cancer.Cellular Prion Protein Enhances Drug Resistance of Colorectal Cancer Cells via Regulation of a Survival Signal Pathway.Invitro Evaluation of Torin2 and 2, 6-Dihydroxyacetophenone in Colorectal Cancer Therapy.Drug resistance related to aberrant glycosylation in colorectal cancer.Targeted photodynamic therapy as potential treatment modality for the eradication of colon cancer and colon cancer stem cells.In vivo and in vitro induction of the apoptotic effects of oxysophoridine on colorectal cancer cells via the Bcl-2/Bax/caspase-3 signaling pathway.PIK3R3 promotes chemotherapeutic sensitivity of colorectal cancer through PIK3R3/NF-kB/TP pathway.CK1α overexpression correlates with poor survival in colorectal cancer.The novel strategies for next-generation cancer treatment: miRNA combined with chemotherapeutic agents for the treatment of cancer.Pramlintide, an antidiabetic, is antineoplastic in colorectal cancer and synergizes with conventional chemotherapy.Chemopreventive activity of celastrol in drug-resistant human colon carcinoma cell cultures.Targeting Oxidatively Induced DNA Damage Response in Cancer: Opportunities for Novel Cancer Therapies.Conception, synthesis, and characterization of a rofecoxib-combretastatin hybrid drug with potent cyclooxygenase-2 (COX-2) inhibiting and microtubule disrupting activities in colon cancer cell culture and xenograft models.Inhibition of Fas associated phosphatase 1 (Fap1) facilitates apoptosis of colon cancer stem cells and enhances the effects of oxaliplatin.Doxorubicin resistance induces IL6 activation in the colon cancer cell line LS1804-Acetyl-Antroquinonol B Suppresses SOD2-Enhanced Cancer Stem Cell-Like Phenotypes and Chemoresistance of Colorectal Cancer Cells by Inducing hsa-miR-324 re-ExpressionmiRNAs and lncRNAs as Predictive Biomarkers of Response to FOLFOX Therapy in Colorectal CancerChemotherapy re-challenge response rate in metastatic colorectal cancer
P2860
Q37098697-FC948B31-1348-4F8D-8ED7-0FA67F7E4D4EQ37285595-7D009B06-B412-4F33-B957-76A7ED91B7BBQ37618598-77E72EF3-FA8C-4D41-BFC7-E95D8EBBECE3Q39016759-5EAF832D-3D29-4BFA-8C2E-DA2CE51A3EFEQ39110060-432564D9-7450-498D-9F99-A76DD95D08B1Q41191235-E80BD1EA-9A82-4295-8142-C3411970A7D8Q41342397-15DFAC21-8A04-4F55-B770-791D11D9F975Q41943341-C8C30591-8398-4829-AB0D-44AE7D2F9A1EQ47098816-820A9532-55A6-4DDE-B34C-5CC62FF1AA2EQ47104929-882ECA42-BE12-4CD8-9DED-D7E4983BB59FQ47106034-7C1FD095-A190-43BD-AA14-7091806E1CCFQ47233779-EFC3AD1A-BEB8-49B4-88E2-19E0E690B92CQ47931139-279F1C6F-0519-45B2-B8C2-7D7E8FE32B3BQ48364896-EC2B008E-127F-4F7F-B2A8-0D0C10BAC0A2Q49185043-C592A72C-FAFE-4D3A-B86C-22FA69C28205Q49486366-6AEFFE8C-CCFD-4F69-8EA1-8316FAC9FA23Q49535148-13BC941D-ACB2-4F8C-A1EF-DE889DA3FFA2Q49689620-FF5F27C7-41C8-4863-9B75-8FA551299F8BQ50057974-D3C29E8E-DEC0-4D08-803E-66D2D37F737BQ51764980-EF8C8CC4-FB3E-48C5-8E8E-43FC137C7F9DQ52649897-46BEDC61-0859-4974-B55C-30C5C860C6EEQ53681639-C2C077B8-638D-466F-B76C-BC88D644F5BAQ55100687-1C6A70C9-D248-4A5F-ACB6-D597A66298FDQ55190499-8688E1ED-2F9A-42D4-851A-AFE80378EA96Q55285088-65CE5542-FA6F-4291-9A5E-0D1FBF3856CFQ57788731-8C808891-227D-4EC2-9065-9A83BB8D307FQ58789473-1E18EF39-7366-42E4-BEA9-CBF16DDE3F13Q58799032-7D7B54CA-26C6-4095-B368-EB845CCCA2AAQ58806053-B18C377E-0052-4A23-AB05-F3B1C9CF7133
P2860
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Pharmacologic resistance in colorectal cancer: a review
@ast
Pharmacologic resistance in colorectal cancer: a review
@en
Pharmacologic resistance in colorectal cancer: a review
@nl
type
label
Pharmacologic resistance in colorectal cancer: a review
@ast
Pharmacologic resistance in colorectal cancer: a review
@en
Pharmacologic resistance in colorectal cancer: a review
@nl
prefLabel
Pharmacologic resistance in colorectal cancer: a review
@ast
Pharmacologic resistance in colorectal cancer: a review
@en
Pharmacologic resistance in colorectal cancer: a review
@nl
P2860
P3181
P356
P1476
Pharmacologic resistance in colorectal cancer: a review
@en
P2093
Abhisek Swaika
Kabir Mody
P2860
P3181
P356
10.1177/1758834015614530
P407
P577
2016-01-01T00:00:00Z